SIlver Trend Alerts: 28th April 2011 (9000% return in 6 months)

By Editorial Team -
This is a performance update. Those who have followed my advice on Silver (XAG/USD) 9 Feb 2011 post and hold your position until now would know that you have made at least 60% on your capital (over a period of less than 3 months). That's not bad a performance compared to your usual unit trust or mutual fund investment. The more savvy ones who leverage 100 times through the brokers that I have recommended would have made 6000 %. Sound impossible?

Better still, those who have followed my advice in November last year would have made close to 9000 %. By the way, you may be in a disbelief but there was no complicated strategy involved. Feel free to comment.

Comments

Post a Comment

Pages

Popular posts from this blog

Top 10 Drugs by Worldwide Sales in 2024

By Editorial Team -
Image
It's been several years since COVID-19 vaccines from Pfizer and Moderna jumped to the top of the pharma industry's sales charts, displacing longtime stalwarts with unprecedented sales. But, as 2023 featured major patent expirations, the rise of weight loss drugs and other new dynamics, the year’s ranking of the top 10 drugs by global sales featured its fair share of surprises. Merck’s oncology king Keytruda rose to the top last year, adding yet another feather in its cap. With more than 30 indications across various cancer types and stages, the PD-L1 inhibitor shows no signs of stopping. With $25 billion in global sales, the drug accounted for about 40% of Merck’s total revenue last year. Keytruda's sales are expected to reach $30 billion this year. Keytruda had previously fallen right behind AbbVie's Humira, which held the title of the world’s bestselling drug for nine years in a row until Pfizer and BioNTech’s Comirnaty knocked AbbVie’s Humira off its perch in 2021. N...
Read more

Top 10 Pharmaceutical Companies by Revenue in 2025

By Editorial Team -
Image
Only one of the top 10 drugmakers, Eli Lilly, is expected to achieve a double-digit revenue increase by the end of 2025. Eli Lilly is projecting a robust growth of around 32% in 2025 compared to 2024, driven by strong sales of its diabetes and weight-loss drugs such as Mounjaro and Zepbound, with full-year revenue guidance between $58 billion and $61 billion ( 1 ,  2 ,  3 ). In contrast, most of the other top 10 pharmaceutical companies are expected to see more moderate revenue growth, generally in the range of 6% to 9% by the end of 2025. This reflects steady but less dramatic expansion compared to Eli Lilly’s exceptional performance ( 4 ). Lilly—boosted by sales of its diabetes and obesity drugs Moujaro and Zepbound— projects  its sales to fall between $58 billion and $61 billion. At the midpoint of the projection, it would be a 32% increase, matching the sales boom it saw last year. Meanwhile, Novo—which also has been powered by sales of its diabetes and obesity treatm...
Read more

7 Best Crypto Exchanges Malaysia 2025

By Editorial Team -
Image
If you're looking for the best cryptocurrency exchanges in Malaysia in 2025, it's important to choose platforms that are secure and fully compliant with local regulations. In Malaysia, Digital Asset Exchanges (DAX) are regulated and licensed by the Securities Commission Malaysia (SC), which ensures they meet strict standards for investor protection and legal compliance. Luno, Binance, Sinegy, Tokenize Exchange, MX Global, Hata and Torum are popular choices. The best cryptocurrency exchanges work similarly to the best stock trading apps, offering competitive fees and resources on digital marketplaces like mobile or desktop. Crypto enthusiasts can easily buy, sell, and store popular digital currencies like Bitcoin or altcoins like Ethereum. Note that if you don't want to use your exchange's built-in wallet (if applicable), you'll need to set up an external crypto wallet, to store your assets securely. Here are details of cryptocurrency exchanges you can use to buy Bit...
Read more

5 Top Silver ETFs 2025: What You Need to Know

By Editorial Team -
Image
Along with gold, silver is in high demand as precious metals are highly sought after as safe havens in uncertain economic environments, boosting prices and assets for top silver ETFs like the iShares Silver Trust (SLV). Investors use silver ETFs for various purposes. Other than its safe-haven benefits, some invest for speculative reasons, hoping to profit from potential increases in silver prices or as a hedge against geopolitical turmoil or currency devaluation. Keep reading to learn more about investing in silver and see a list of top ETFs investing in the precious metal.   What Are Silver ETFs?  Silver ETFs are exchange-traded funds that provide exposure to the price of silver, a precious metal. These ETFs are designed to track the performance of silver prices, making it easier for investors to gain exposure to the silver market without physically owning and storing the metal itself. Silver's unique combination of properties, including its electrical conductivity, thermal c...
Read more

Top 10 Pharma Companies by R&D Spend 2024

By Editorial Team -
Image
In 2024, the pharmaceutical industry witnessed significant shifts in research and development (R&D) investments, with companies like Merck & Co. and AstraZeneca making notable strategic decisions that impacted their positions among top R&D spenders. The average cost for major pharmaceutical companies to develop a drug in 2024 rose to $2.23 billion, up from $2.12 billion the previous year. This increase reflects the growing complexity and expense associated with bringing new therapies to market. ​( Fierce Biotech ) These developments illustrate the dynamic nature of R&D investments in the pharmaceutical sector, influenced by strategic partnerships, acquisitions, and the escalating costs of drug development. 1. Merck & Co. R&D SPENDING 2024: $17.9 billion Change from 2023: -41% Total 2024 revenue: $64.2 billion R&D budget as percentage of revenue: 28% Market capitalisation: 198.3 B USD (as of June 2025) Merck & Co.’s R&D spending plummeted from the d...
Read more

Pharma & Cancer Treatment 2025: Breakthroughs, Market Leaders, and Industry Trends

By Editorial Team -
Image
The landscape of cancer treatment and the pharmaceutical industry is undergoing rapid transformation in 2025, driven by scientific breakthroughs, shifting drug sales rankings, and evolving strategies among top pharma companies. This article synthesizes the latest advances in cancer therapy, highlights the world’s top-selling drugs, and examines the leading pharmaceutical players shaping the future of oncology and global health. Latest Breakthroughs in Cancer Treatment (2025) The fight against cancer is being reshaped by a wave of innovations, many of which are already impacting clinical practice or are in advanced stages of development: Next-Generation Immunotherapy New checkpoint inhibitors, CAR-T cell therapies, and bispecific antibodies are expanding options for hard-to-treat cancers such as pancreatic and brain tumors. Related:   Combining Repurposed Drugs with Immunotherapy : A Novel Approach to Cancer Treatment AI-Based Risk Profiling AI and machine learning are being used fo...
Read more

Bitcoin Nasdaq Correlation: The Correlation between the Nasdaq index and Cryptocurrencies 2025

By Editorial Team -
Image
The correlation between the Nasdaq index and cryptocurrencies, particularly Bitcoin, has been a subject of interest and analysis, reflecting the increasing integration of digital assets into the broader financial ecosystem. Here's a detailed look at this relationship: Historical Context and Trends: Increasing Correlation : Over the past few years, there has been a noticeable trend towards a stronger correlation between Bitcoin and the Nasdaq Composite Index, especially with tech-heavy indices like the Nasdaq 100. As of early 2025, this correlation has been observed to be at a high level, with some periods showing a correlation coefficient above 0.9. This suggests that movements in Bitcoin prices often mirror those of the Nasdaq, particularly during bullish market phases for tech stocks. Institutional Influence : The growing involvement of institutional investors in cryptocurrencies has played a significant role in this correlation. Companies like Coinbase, which has a listing on Na...
Read more

10 Best E Wallets in Malaysia 2025

By Editorial Team -
Image
An e-wallet or a digital wallet is a feature within an app that allows transactions to be made via a smartphone. Similar to a traditional 'wallet', the e-wallet stores digital cash instead of physical cash. The prominence of e-wallets in Malaysia has grown significantly in the past few years, with its huge growth mainly driven by the government’s efforts and active marketing efforts by various companies. Credit: CompareHero.my Let’s check out the popular eWallets in Malaysia now with their payment method, top up method and other features as below: 1) E Wallet Touch 'n GO Malaysia Courtesy of tngdigital.com.my TouchnGO eWallet is owned by TNG Digital Sdn Bhd, It’s an all in one e-wallet service covering all existing and future Touch ‘n Go products & services, with the Slogan “Shaping the future of e-payments for Malaysians”. Payment Method : QR Code Transfer to Friends : Yes, with Phone Number Top Up Method : FPX, Credit or Debit Card, Reload Pin, or Auto Reload Merchant...
Read more

Top 10 Drugs by Worldwide Sales in 2025

By Editorial Team -
Image
The pharmaceutical market in 2025 continues to be led by innovative therapies addressing cancer, metabolic diseases, autoimmune conditions, and chronic illnesses. Below is an updated overview of the top 10 drugs by projected global sales in 2025. Highlights and Market Trends Keytruda (Pembrolizumab) remains the global leader in drug sales with projected revenues exceeding $31 billion in 2025. This cancer immunotherapy has expanded to over 40 approved indications since its launch in 2014, including multiple cancer types, driving strong sales growth. Merck reported $21.6 billion in sales for the first three quarters of 2024, an 18% increase year-on-year ( 2 ,  5 ,  7 ) . GLP-1 receptor agonists dominate the metabolic therapy segment with four drugs in the top 10: Ozempic and Wegovy (both semaglutide-based), Mounjaro and Zepbound (tirzepatide-based). These drugs are primarily used for type 2 diabetes and obesity management, reflecting the growing global focus on metabolic di...
Read more

12 Best SME Business Loans in Malaysia 2025

By Editorial Team -
Image
Several banks in Malaysia offer business loans tailored for SMEs. Maybank and CIMB are popular choices, offering a variety of loan amounts and competitive interest rates. Other notable options include Public Bank and RHB, while SME Bank and MIDF also provide dedicated financing solutions for small and medium-sized enterprises.   SME or also known as Small and Medium-sized Enterprises are businesses that maintain revenues, assets, or a number of employees below a certain threshold. These business entities are often regarded as the heartbeat of Malaysia’s emerging and developing economies. Apart from providing vast numbers of employment opportunities, SME businesses are generally entrepreneurial in nature, helping to shape innovation. Generally, there are two criteria to be met in order for your business to qualify as an SME -- your annual sales turnover and the number of full time employees in your company. This also implies differently for each economy sector: Manufacturing (S...
Read more